Scarica l'app Stockscreener
17.94
0.17%
-0.03
Dopo l'orario di chiusura:
17.94
Precedente Chiudi:
$17.97
Aprire:
$17.93
Volume 24 ore:
335.98K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.32B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.86%
1M Prestazione:
-5.63%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.47
$18.39
Intervallo di 1 settimana:
$17.47
$19.51
Portata 52W:
$16.39
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Nome
Kailera Therapeutics Inc
Settore
Industria
Telefono
508-440-9475
Indirizzo
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
17.94 | 2.41B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-12 | Iniziato | Evercore ISI | Outperform |
| 2026-05-12 | Iniziato | JP Morgan | Overweight |
| 2026-05-12 | Iniziato | Jefferies | Buy |
| 2026-05-12 | Iniziato | Leerink Partners | Outperform |
| 2026-05-12 | Iniziato | TD Cowen | Buy |
| 2026-05-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Kailera Therapeutics Inc Borsa (KLRA) Ultime notizie
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - moomoo.com
KLRA SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing - GuruFocus
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Nigeria
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kailera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Kailera Therapeutics Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView
Jiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing - Stock Titan
Bain Capital Xiv General Partner, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. Revenue Breakdown – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat
Patent fight erupts around next generation of multibillion-dollar GLP-1 weight-loss drugs - The Business Journals
Yuting Liu Net Worth (2026) - GuruFocus
Jamie Beth Coleman Net Worth (2026) - GuruFocus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Net Worth (2026) - GuruFocus
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Scott M. Wasserman Net Worth (2026) - GuruFocus
Stuart Partners, Llc Net Worth (2026) - GuruFocus
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowWhat's Next? - MarketBeat
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Kailera's obesity drug meets main goal of late-stage trials in China - MSN
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win - Seeking Alpha
5 Best IPO Stocks with Huge Upside Potential - Insider Monkey
Kailera Therapeutics (KLRA) officer receives 175,000 stock options at $23.30 strike - Stock Titan
Kailera Therapeutics (KLRA) officer Kathleen Tregoning files initial Form 3 - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Kailera weight loss pill trial results: Nausea sinks stock - qz.com
Europe will accelerate its review of RevMed’s drug - STAT
Kailera reports positive Phase III data for oral GLP-1 obesity candidate - The Pharma Letter
Kailera shares tumble on high nausea rates despite weight-loss drug's success | Business Information & News | FE - Westlaw Today
Kailera Therapeutics (KLRA) Company presentation Summary - Quartr
Kailera Therapeutics (KLRA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Kailera Therapeutics (KLRA) Registration filing Summary - Quartr
Kailera falls after late-stage trial data for oral GLP-1 candidate - MSN
Kailera/Hengrui’s Oral GLP-1 Looks Effective, But GI Toxicity Raises Concern - insights.citeline.com
Kailera shares tumble on high nausea rates despite weight-loss drug's success - MSN
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall - Moomoo
Kailera shares tumble on high nausea rates despite weight-loss drug’s success - Y100 WNCY
Kailera Therapeutics Inc Azioni (KLRA) Dati Finanziari
Non sono disponibili dati finanziari per Kailera Therapeutics Inc (KLRA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):